A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma
Public ClinicalTrials.gov record NCT03273153. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Open-Label, Multicenter, Two Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase III, multicenter, open-label, randomized study designed to evaluate the efficacy, safety, and pharmacokinetics of cobimetinib plus atezolizumab compared with pembrolizumab in treatment-naive participants with advanced BRAFV600 wild-type melanoma.
Study identification
- NCT ID
- NCT03273153
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 446 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 11, 2017 (Actual)
- Primary completion
- Apr 15, 2019 (Actual)
- Completion
- Feb 19, 2021 (Actual)
- Last update posted
- Sep 21, 2022
2017 – 2021
United States locations
- U.S. sites
- 23
- U.S. states
- 14
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arizona Cancer Center | Tucson | Arizona | 85719 | — |
| City of Hope Comprehensive Cancer Center | Duarte | California | 91010 | — |
| USC Norris Cancer Center | Los Angeles | California | 90033 | — |
| USC Norris Cancer Center; USC Oncology Hematology Newport Beach | Newport Beach | California | 92663 | — |
| University of California at Irvine Medical Center; Department of Oncology | Orange | California | 92868 | — |
| Stanford Comprehensive Cancer Center | Stanford | California | 94305 | — |
| UF Health Cancer Center at Orlando Health | Orlando | Florida | 32824 | — |
| Florida Cancer Specialist, North Region | St. Petersburg | Florida | 33705 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Florida Cancer Specialists | West Palm Beach | Florida | 33401 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| Massachusetts General Hospital;Hematology/ Oncology | Boston | Massachusetts | 02114 | — |
| University of Michigan; Michigan Institute for Clinical and Health Research (MICHR) | Ann Arbor | Michigan | 48109 | — |
| Dartmouth-Hitchcock Medical Center; Hematology/Oncology | Lebanon | New Hampshire | 03756 | — |
| Morristown Medical Center | Morristown | New Jersey | 07962 | — |
| Forsythe Memorial Hospital Inc., dba Novant Health Oncology Specialists | Winston-Salem | North Carolina | 27103 | — |
| TriHealth Hatton Institute; Surgical Education | Cincinnati | Ohio | 45220 | — |
| St. Luke's University Health network | Bethlehem | Pennsylvania | 18015 | — |
| Thomas Jefferson University Hospital;Medical Oncology | Philadelphia | Pennsylvania | 19107 | — |
| SCRI Tennessee Oncology Chattanooga | Chattanooga | Tennessee | 37404 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| M.D Anderson Cancer Center; Uni of Texas At Houston | Houston | Texas | 77030 | — |
| West Virginia University Hospitals Inc | Morgantown | West Virginia | 26056 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 98 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03273153, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 21, 2022 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03273153 live on ClinicalTrials.gov.